Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy
Frontiers of Medicine · 2023-08 · 17 (4) · 699-713
DOI: 10.1007/s11684-022-0972-8 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Frontiers of Medicine, online erschienen am 15.04.2023. Verfasst von Zixun Yan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Tumor Microenvironment, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%-50% long-term complete response in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients. However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cell therapy failure needs further investigation. A multi-center phase I/II trial of anti-CD19 CD28z CAR-T (FKC876, ChiCTR1800019661) was conducted. Among 22 evaluable DLBCL patients, seven achieved complete remission, 10 experienced partial remissions, while four had stable disease by day 29. Single-cell RNA sequencing results were obtained from core needle biopsy tumor samples collected from long-term complete remission and early-progressed patients, and compared at different stages of treatment. M2-subtype macrophages were significantly involved in both in vivo and in vitro anti-tumor functions of CAR-T cells, leading to CAR-T cell therapy failure and disease progression in DLBCL. Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansion and disease progression, which could not be altered by infiltrating CAR-T cells. Aberrant metabolism profile of M2-subtype macrophages and those of dysfunctional T cells also contributed to the immunosuppressive tumor microenvironments. Thus, our findings provided a clinical rationale for targeting tumor microenvironments and reprogramming immune cell metabolism as effective therapeutic strategies to prevent lymphoma relapse in future designs of CAR-T cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
- University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
- Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.
- Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300070, China.
- Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Shanghai, 200025, China. zhao.weili@yahoo.com.
Zitieren
APA
Yan, Z., Li, L., Fu, D., Wu, W., Qiao, N., Huang, Y., Jiang, L., Wu, D., Hu, Y., Zhang, H., Xu, P., Cheng, S., Wang, L., Lacin, S., Muftuoglu, M., & Zhao, W. (2023). Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Frontiers of Medicine, 17(4), 699-713. https://doi.org/10.1007/s11684-022-0972-8
Vancouver
Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y, et al. Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Frontiers of Medicine. 2023;17(4):699-713. doi:10.1007/s11684-022-0972-8
BibTeX
@article{Yan2023,
author = {Yan, Zixun and Li, Li and Fu, Di and Wu, Wen and Qiao, Niu and Huang, Yaohui and Jiang, Lu and Wu, Depei and Hu, Yu and Zhang, Huilai and Xu, Pengpeng and Cheng, Shu and Wang, Li and Lacin, Sahin and Muftuoglu, Muharrem and Zhao, Weili},
title = {Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy},
journal = {Frontiers of Medicine},
year = {2023},
volume = {17},
number = {4},
pages = {699--713},
doi = {10.1007/s11684-022-0972-8}
}
EUVIMED